MarketWatch · Oct 3, 2023
Does anyone want to buy bankrupt SmileDirectClub?
The company, which has been controversial and combative ever since it went public in 2019, may have an extremely hard time finding a buyer.
SD
NASDAQ · SDC
SmileDirectClub, Inc.
Healthcare · Medical - Instruments & Supplies
$0.08
Down-$0.09 (-53.45%)
Updated Sep 10, 2026, 6:24 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 29.11M
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 63.4M
- Avg. volume
- 4.51M
Price performance
SDC price history
1M range · 0 trading sessions · Daily adjusted prices
SDC does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest SDC news
The latest Smart Investors Daily articles mentioning SDC.
Stock researchCompany · Overview
SDC research
Overview
Company profile and research snapshot.
Company profile
SmileDirectClub, Inc., an oral care company, offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a doctor, and monitoring through completion of their treatment with a network of approximately 250 licensed orthodontists and general dentists through its teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, France, Spain, and Austria. It also offers aligners, impression and whitening kits, whitening gels, and retainers; and toothbrushes, toothpastes, water flossers, SmileSpa, and various ancillary oral care products. The company was founded in 2014 and is headquartered in Nashville, Tennessee.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $5.05
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 8, 2022 | Loop Capital | Hold | — |
| Aug 10, 2022 | Morgan Stanley | Equal-Weight | — |
| Aug 9, 2022 | Morgan Stanley | Equal-Weight | — |
| Jun 17, 2022 | Stifel | Hold | — |
| Jun 15, 2022 | Morgan Stanley | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 3, 2023
Nasdaq Down Over 200 Points; US Job Openings Rise In August
U.S. stocks extended losses midway through trading, with the Nasdaq Composite falling more than 200 points on Tuesday. The Dow traded down 1.06% to 33,078.27 while the NASDAQ fell 1.60% to 13,094.83. The S&P 500 also fell, dropping, 1.27% to 4,233.76. Check This Out: Vivani Medical And 3 Other Stocks Under $2 Insiders Are Buying Leading and Lagging Sectors Materials shares fell by just 0.1% on Tuesday. In trading on Tuesday, consumer discretionary shares dipped by around 2%. Top Headline The number of job openings increased by 690,000 from the prior month to 9.61 million in August, compared to market estimates of 8.8 million. Equities Trading UP Vericity, Inc. (NASDAQ: VERY) shares shot up 87% to $11.06 after iA Financial Group announced it will acquire the company. Shares of POINT Biopharma Global Inc. (NASDAQ: PNT) got a boost, shooting 85% to $12.39. Eli Lilly And Co (NYSE: LLY) agreed to acquire POINT Biopharma Global at $12.50 per share in cash, an aggregate of approximately $1.4 billion. SciSparc Ltd. (NASDAQ: SPRC) shares were also up, gaining 33% to $4.8839 ...
Benzinga · Oct 3, 2023
Dow Falls Over 100 Points; McCormick Sales Miss Views
U.S. stocks traded lower this morning, with the Dow Jones falling more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.37% to 33,310.99 while the NASDAQ fell 0.58% to 13,230.96. The S&P 500 also fell, dropping, 0.47% to 4,268.18. Check This Out: Vivani Medical And 3 Other Stocks Under $2 Insiders Are Buying Leading and Lagging Sectors Consumer staples shares fell by just 0.04% on Tuesday. In trading on Tuesday, consumer discretionary shares dipped by around 1%. Top Headline McCormick & Company, Incorporated (NYSE: MKC) reported weaker-than-expected sales for its third quarter. The company posted third-quarter FY23 sales growth of 6% year-on-year to $1.684 billion, missing the analyst consensus estimate of $1.70 billion. Adjusted EPS of $0.65 was in line with the consensus estimate. McCormick reaffirmed FY23 revenue growth guidance of 5% - 7%. The company raised FY23 adjusted EPS outlook to $2.62 - $2.67 from $2.60 - $2.65. Equities Trading UP Vericity, Inc. (NASDAQ: VERY) shares shot up 87% to $11.11 after iA Financial Group announced it will acquire the company. Shares of POINT Biopharma Global Inc. (NASDAQ: PNT) got a ...
MarketWatch · Oct 2, 2023
Dow declines for eighth time in 10 sessions as bond yields rise even further
U.S. stocks end mostly higher Monday to begin the final quarter of 2023, but investors remain uneasy about rising Treasury yields.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
